Plasmapheresis Therapy in Kidney Transplant Rejection

2018 ◽  
Vol 47 (1-3) ◽  
pp. 73-84 ◽  
Author(s):  
Pan Xie ◽  
Min Tao ◽  
Kanfu Peng ◽  
Hongwen Zhao ◽  
Keqin Zhang ◽  
...  
Keyword(s):  
End Stage Renal Disease ◽  
Multimodal Treatment ◽  
Transplant Rejection ◽  
Human Leukocyte ◽  
Economic Costs ◽  
Leukocyte Antigen ◽  
Antibody Mediated Rejection ◽  
Stage Renal Disease ◽  
End Stage ◽  
Optimal Treatment Strategy

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients

2014 ◽  
Vol 75 (6) ◽  
pp. 531-535 ◽  
Author(s):  
Shih-Yuan Hung ◽  
Tsun-Mei Lin ◽  
Min-Yu Chang ◽  
Hsi-Hao Wang ◽  
Yi-Che Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Disease ◽  
Human Leukocyte Antigen ◽  
End Stage Renal Disease ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Revisiting the Association between Human Leukocyte Antigen and End-Stage Renal Disease

2020 ◽  
Author(s):  
Naila Noureen ◽  
Farhad Ali Shah ◽  
Jan Lisec ◽  
Hina Usman ◽  
Mohammad Khalid ◽  
...  
Keyword(s):  
Renal Disease ◽  
Human Leukocyte Antigen ◽  
Ethnic Groups ◽  
End Stage Renal Disease ◽  
Human Leukocyte ◽  
Hla Polymorphism ◽  
Hla Alleles ◽  
Leukocyte Antigen ◽  
Stage Renal Disease ◽  
End Stage

AbstractMultiple works have studied possible associations between human leukocyte antigen (HLA) alleles and end stage renal disease (ESRD) showing, however, contradictory and inconsistent results. Here, we revisit the association between ESRD and HLA antigens, comparing HLA polymorphism (at HLA-A, -B, -C, -DRB1, -DQB1 and DQA1 loci) in ESRD patients (n=497) and controls (n=672). Our data identified several HLA alleles that displayed a significant positive or negative association with ESRD. We also determined whether heterozygosity or homozygosity of the ESRD-associated HLA alleles at different loci could modify the prevalence of the disease. Few HLA allele combinations displayed significant associations with ESRD among which HLA-A*3–HLA-A*26 combination showed the highest strength of association (OR= 4.488, P≤ 0.05) with ESRD. Interestingly, the age of ESRD onset was not affected by HLA allele combinations at different loci. We also performed an extensive literature analysis to determine whether the association of HLA to ESRD can be similar across different ethnic groups. Our analysis showed at least for certain alleles, HLA-A*11, HLA-DRB1*11, and HLA-DRB1*4, a significant association of HLA to ESRD in different ethnic groups. The findings of our study will help in determining possible protective or susceptible roles of various HLA alleles in ESRD.

scholarly journals Revisiting the association between human leukocyte antigen and end-stage renal disease

PLoS ONE ◽  
2020 ◽  
Vol 15 (9) ◽  
pp. e0238878
Author(s):  
Naila Noureen ◽  
Farhad Ali Shah ◽  
Jan Lisec ◽  
Hina Usman ◽  
Mohammad Khalid ◽  
...  
Keyword(s):  
Renal Disease ◽  
Human Leukocyte Antigen ◽  
End Stage Renal Disease ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Hani Susianti ◽  
Dwi Priyadi Djatmiko ◽  
I Komang Adi Widana ◽  
Deasy Ayuningtyas Tandio ◽  
Catur Suci Sutrisnani ◽  
...  
Keyword(s):  
Renal Disease ◽  
Human Leukocyte Antigen ◽  
End Stage Renal Disease ◽  
Human Leukocyte ◽  
Class I ◽  
Leukocyte Antigen ◽  
Hla Genes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background. Genetic studies of end-stage renal disease (ESRD), including those of human leukocyte antigen (HLA) genes, have been reported in several populations but have not yet been evaluated in Indonesia. Some studies have reported that these genes had a substantial role in ESRD. This study aims to analyze the association between HLA genes and ESRD within the Indonesian community. Method. A retrospective study to investigate HLA class I and II alleles to find out the distribution of HLA-A, -B, -C, -DPB1, -DQB1, and -DRB1 in renal transplant recipients and to ascertain their role in susceptibility to ESRD was performed on totally 149 subjects, consisting of 69 ESRD patients and 80 healthy controls. HLA typing was determined using Luminex techniques. The allele and haplotype frequencies were compared between ESRD patients and controls. Result. High-frequency alleles were HLA-A ∗ 24 (43.6%), B ∗ 15 (38.2%), C ∗ 08 (30.8%), DRB1 ∗ 12 (47.3%), DQB1 ∗ 03 (50.6%), and DPB1 ∗ 13 (22.5%). HLA-A ∗ 24 p = 0.01 and HLA-B ∗ 35 p = 0.02 were associated with a protective effect, with OR 0.537 (95%CI 0.34–0.86) and 0.316 (95%CI 0.11–0.88), respectively. There were some two-locus haplotypes associated with susceptibility to ESRD, such as B ∗ 15-DRB1 ∗ 12, B ∗ 13-DRB1 ∗ 15, A ∗ 02-B ∗ 15, A ∗ 02-C ∗ 08, and B ∗ 13-DQB1 ∗ 05. HLA-A ∗ 02-B ∗ 15-DRB1 ∗ 12 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 appear to be associated with susceptibility to ESRD. Conclusion. The allele groups of HLA-A ∗ 24 and HLA-B ∗ 35 are associated with protection from ESRD. Meanwhile, HLA-B ∗ 13-DRB1 ∗ 15 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 are the most frequent HLAs associated with ESRD in two-locus and three-locus haplotype, respectively.

Kidney Transplantation 1: An Overview--Recipient Evaluation and Immunosuppression

2017 ◽  
Author(s):  
Belinda T. Lee ◽  
Anil Chandraker ◽  
Jamil Azzi ◽  
Martina M McGrath
Keyword(s):  
Kidney Transplantation ◽  
Human Leukocyte ◽  
Basic Knowledge ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Early Management ◽  
Leukocyte Antigen ◽  
Medical Evaluation ◽  
Stage Renal Disease ◽  
End Stage

Kidney transplantation remains the optimal renal replacement therapy for patients with end-stage renal disease (ESRD). A timely referral to kidney transplantation and a thorough pretransplantation evaluation ensure improvement in the morbidity and mortality of ESRD patients. Basic knowledge of immune biology and an in-depth understanding of the different induction and maintenance therapies used post kidney transplantation are imperative for optimal patient management. In this review, we discuss the multidisciplinary process of pretransplantation evaluation of kidney transplant recipients. We also discuss state-of–the-art early management post kidney transplantation with the different immunosuppressive therapies currently available. This review contains 3 figures, 11 tables, and 106 references. Key words: crossmatch, donor-specific antibody, immunosuppression, human leukocyte antigen, immunosuppression, induction, maintenance, medical evaluation, transplantation

Sign in / Sign up

Export Citation Format

Share Document